SFM
MRSN

Sphera Funds Management’s Mersana Therapeutics MRSN Stock Holding History

Sphera Funds Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,611
Closed -$987K – 124
2024
Q4 		$987K Buy
+27,611
New +$1.43M 0.18% 92
2023
Q3 		– Sell
-16,742
Closed -$1.38M – 95
2023
Q2 		$1.38M Buy
16,742
+16,317
+3,839% +$2.39M 0.22% 78
2023
Q1 		$43.7K Buy
+425
New +$59.7K 0.01% 81
2019
Q4 		– Sell
-8,000
Closed -$316K – 94
2019
Q3 		$316K Hold
8,000
– – 0.05% 78
2019
Q2 		$810K Hold
8,000
– – 0.11% 80
2019
Q1 		$1.05M Buy
+8,000
New +$1.01M 0.1% 92

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sphera Funds Management's MRSN Position: Q1 2025 in Review

Sphera Funds Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 27,611 shares — an estimated $987K sold.

Sphera Funds Management first reported a position in MRSN in Q1 2019 and held it in 6 quarters. The position peaked at $1.38M in Q2 2023. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Sphera Funds Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sphera Funds Management sold 27,611 Mersana Therapeutics shares in Q1 2025, an estimated $987K.
  • Sphera Funds Management first reported a position in Mersana Therapeutics in Q1 2019 and held it in 6 quarters.
  • Sphera Funds Management's Mersana Therapeutics position peaked at $1.38M in Q2 2023.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Sphera Funds Management's 13F filing for Q1 2025, filed 15 May 2025.